Publications by authors named "Y Ubukata"
Introduction: This multicenter study aimed to determine whether the pretreatment prognostic nutrition index (PNI) or a change in the index after two treatment courses could be a biomarker for predicting treatment sensitivity in patients with unresectable advanced or recurrent gastric cancer treated using chemotherapy and nivolumab as the first-line treatment.
Methods: This multicenter retrospective study with 104 patients was conducted at 12 institutions. PNI was calculated before treatment and after two courses of treatment in each case.
Article Synopsis
- The study focused on identifying biomarkers that can predict treatment outcomes and immune-related adverse events in patients with advanced recurrent gastric cancer receiving chemotherapy and nivolumab.
- The research involved 104 patients, analyzing blood tests before and after treatment to assess changes in specific ratios like the lactate dehydrogenase/albumin ratio (LAR).
- Results showed that 54.8% of patients had a positive response to treatment and that the LAR could serve as a potential biomarker for therapeutic response and efficacy.
Article Synopsis
- A multicenter study analyzed data from 104 patients with unresectable advanced or recurrent gastric cancer, focusing on conversion surgery (CS) after chemotherapy plus nivolumab as first-line treatment.
- Out of the patients, 12 (11.5%) underwent CS, with significantly better Eastern Cooperative Oncology Group Performance Status (ECOG-PS) in those who did compared to those who did not.
- The study found no high-risk Gustave Roussy Immune Score (GRIm-s) cases among those who had CS, suggesting that the GRIm-s might serve as a predictive biomarker for successful surgery outcomes.
Article Synopsis
- Gastrectomy with D2 dissection and adjuvant chemotherapy is the usual treatment for locally advanced gastric cancer (LAGC) in Asia, but administering post-surgery chemotherapy can be challenging, especially in older patients.
- This phase II study (KSCC1801) investigated the safety and efficacy of neoadjuvant chemotherapy (NAC-SOX) in patients aged 70 and above, finding that it resulted in a high resection rate (92.3%) and a significant pathological response (62.5%).
- Though NAC-SOX showed promise, there were notable adverse events like neutropenia and a treatment-related death due to severe diarrhea, indicating the need for careful management.